HER3-Targeted Therapies for EGFRm NSCLC: Key Evidence and Real-world Insights to Optimize Patient Care

Enhance your knowledge of HER3 overexpression in EGFR-mutated non-small-cell lung cancer and gain strategies for developing individualized treatment plans incorporating HER3-targeted therapies in patients with acquired resistance to EGFR tyrosine kinase inhibitors, through a series of text modules with accompanying downloadable slidesets and an expert-authored commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.